Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive disease.

Special guest Dr. Harold Burstein from Dana-Farber Cancer Institute shared his insights on the evolving landscape of HER2-positive breast cancer treatment, including the importance of patient selection and the management of side effects like interstitial lung disease (ILD).

Tune in for a comprehensive recap of the latest data, treatment algorithms, and how these advancements are changing the lives of patients with HER2-positive breast cancer.

Don't forget to like, subscribe, and check out our other episodes for more updates on treatment options and conference highlights!

Topics Covered: • DESTINY Breast-11 and its impact on neoadjuvant therapy • Insights from DESTINY Breast-05 on adjuvant treatment for high-risk residual disease • HER2CLIMB-05 trial findings and implications for metastatic disease • The role of T-DXd with pertuzumab in frontline settings • The PATINA trial and its significance for triple-positive metastatic breast cancer

Follow us on social media: •⁠ ⁠X/Twitter: https://twitter.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights!

#SABCS2025 #HER2positive #DestinyTrials #OncologyBrothers #BreastCancer

HER2+ SABCS 2025 Highlights DESTINY Breast-05/Breast-11, HER2CLIMB-05, PATINA: Dr. Harold Burstein

Oncology Brothers: Practice-Changing Cancer Discussions

HER2+ SABCS 2025 Highlights DESTINY Breast-05/Breast-11, HER2CLIMB-05, PATINA: Dr. Harold Burstein